Nexentis Shareholders Approve Reverse Split and Financing Flexibility
TipRanks (Thu, 30-Apr 6:08 PM ET)
Globe Newswire (Fri, 13-Mar 9:15 AM ET)
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Nexentis Technologies trades on the NASDAQ stock market under the symbol NXTS.
As of May 1, 2026, NXTS stock price declined to $4.64 with 15,205 million shares trading.
NXTS has a market cap of $3.39 million. This is considered a Sub-Micro Cap stock.
NXTS support price is $4.36 and resistance is $5.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXTS shares will trade within this expected range on the day.
